• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

种族(亚裔、非裔美国人、欧裔美国人和西班牙裔)与经体重校正的肝素负荷量后行经皮冠状动脉介入治疗患者的活化凝血时间的关系。

Relation of race (Asian, African-American, European-American, and Hispanic) to activated clotting time after weight-adjusted bolus of heparin during percutaneous coronary intervention.

机构信息

Department of Medicine, Beth Israel Medical Center, University Hospital and Manhattan Campus for the Albert Einstein College of Medicine, New York, New York, USA.

出版信息

Am J Cardiol. 2010 Mar 1;105(5):629-32. doi: 10.1016/j.amjcard.2009.10.043.

DOI:10.1016/j.amjcard.2009.10.043
PMID:20185008
Abstract

A weight-adjusted bolus of heparin (70 to 100 IU/kg) is recommended to achieve adequate anticoagulation during percutaneous coronary intervention (PCI). Proper dosing is mandatory to avoid bleeding and thrombotic complications. We investigated whether sensitivity to heparin is affected by difference in race. We performed a retrospective study with 874 consecutive PCI cases in our catheterization laboratory. The amount of initial heparin bolus (international units) per weight and subsequent activated clotting time (ACT; seconds) were obtained. Patients were divided into 4 categories based on race: Asian, African-American, European-American, and Hispanic. Multiple regression analysis was performed to validate the variables that determine the ACT. After adjusting for these variables, analysis of variance revealed the presence of a significant racial difference in ACT (p = 0.002). Successively, Student-Newman-Keuls test and Bonferroni t test revealed that Asian patients have higher ACT levels compared to other racial groups (p <0.03 for Asian vs others, p >0.26 between non-Asian groups). There was a positive relation between ACT and Asian race (p = 0.0004). Further analyses showed that Asians require 10 IU/kg less heparin per weight than other racial groups to achieve the same goal of ACT. In conclusion, decreased heparin dosing should be considered for Asian patients undergoing PCI.

摘要

建议在经皮冠状动脉介入治疗(PCI)期间,根据体重给予调整剂量的肝素(70-100IU/kg)以达到充分抗凝。适当的剂量是避免出血和血栓并发症的必要条件。我们研究了肝素敏感性是否因种族差异而受到影响。我们对导管室 874 例连续 PCI 病例进行了回顾性研究。获得初始肝素推注量(单位)和随后的激活凝血时间(ACT;秒)。根据种族将患者分为 4 类:亚洲人、非裔美国人、欧裔美国人和西班牙裔。进行多元回归分析以验证确定 ACT 的变量。在调整这些变量后,方差分析显示 ACT 存在显著的种族差异(p = 0.002)。然后,学生新曼-凯斯检验和 Bonferroni t 检验显示亚洲患者的 ACT 水平高于其他种族组(亚洲与其他种族组相比,p <0.03,非亚洲种族组之间,p >0.26)。ACT 与亚洲种族之间存在正相关关系(p = 0.0004)。进一步分析表明,亚洲人在进行 PCI 时,每公斤体重需要的肝素剂量比其他种族少 10IU/kg 即可达到相同的 ACT 目标。总之,对于接受 PCI 的亚洲患者,应考虑减少肝素剂量。

相似文献

1
Relation of race (Asian, African-American, European-American, and Hispanic) to activated clotting time after weight-adjusted bolus of heparin during percutaneous coronary intervention.种族(亚裔、非裔美国人、欧裔美国人和西班牙裔)与经体重校正的肝素负荷量后行经皮冠状动脉介入治疗患者的活化凝血时间的关系。
Am J Cardiol. 2010 Mar 1;105(5):629-32. doi: 10.1016/j.amjcard.2009.10.043.
2
Impact of different Asian ethnic groups on correlation between heparin dose, activated clotting time and complications in percutaneous coronary intervention.
Int J Cardiol. 2008 Nov 28;130(3):500-2. doi: 10.1016/j.ijcard.2007.07.017. Epub 2007 Aug 16.
3
Comparison of activated clotting times to heparin management test for adequacy of heparin anticoagulation in percutaneous transluminal coronary angioplasty.
Cathet Cardiovasc Diagn. 1998 Nov;45(3):329-31. doi: 10.1002/(sici)1097-0304(199811)45:3<329::aid-ccd26>3.0.co;2-q.
4
Heparin dosing for percutaneous coronary angioplasty: use of body surface area to improve initial activated clotting time values.经皮冠状动脉成形术的肝素给药:利用体表面积改善初始活化凝血时间值。
Clin Cardiol. 1997 Dec;20(12):1006-9. doi: 10.1002/clc.4960201206.
5
Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.经皮冠状动脉介入治疗期间活化凝血时间(ACT)指导下的静脉注射达肝素给药。
J Invasive Cardiol. 2008 Jul;20(7):323-7.
6
Anticoagulant Effect of Standard Dose Heparin During Peripheral Endovascular Intervention.标准剂量肝素在周围血管腔内介入治疗中的抗凝作用。
Ann Vasc Surg. 2019 Oct;60:286-292. doi: 10.1016/j.avsg.2019.02.033. Epub 2019 May 7.
7
Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results.低剂量普通肝素在经皮冠状动脉血运重建术中的安全性和有效性以及活化凝血时间与出血或缺血性并发症之间的关系:我们的研究结果
J Cardiovasc Med (Hagerstown). 2006 Dec;7(12):866-71. doi: 10.2459/01.JCM.0000253830.64753.0b.
8
Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).经皮腔内冠状动脉成形术(PTCA)患者中肝素以及肝素与血小板糖蛋白IIb/IIIa受体抗体片段阿昔单抗(c7E3)联合用药的实验室监测。
Herz. 2003 Aug;28(5):445-52. doi: 10.1007/s00059-003-2349-3.
9
Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention in acute myocardial infarction: a VALIDATE-SWEDEHEART substudy.在急性心肌梗死经皮冠状动脉介入治疗中,接受强效 P2Y12 抑制剂且无计划使用糖蛋白 IIb/IIIa 抑制剂的患者中,肝素抗凝程度与临床结局的关系:VALIDATE-SWEDEHEART 亚研究。
Eur Heart J Cardiovasc Pharmacother. 2020 Jan 1;6(1):6-13. doi: 10.1093/ehjcvp/pvz015.
10
What is the optimal anticoagulation level with argatroban during percutaneous coronary intervention?在经皮冠状动脉介入治疗期间,使用阿加曲班的最佳抗凝水平是多少?
Blood Coagul Fibrinolysis. 2008 Jul;19(5):401-4. doi: 10.1097/MBC.0b013e328304e00d.

引用本文的文献

1
Clopidogrel therapy in acute coronary syndrome: Contemporary issues.急性冠状动脉综合征中的氯吡格雷治疗:当代问题
Indian Heart J. 2025 Jul-Aug;77(4):311-317. doi: 10.1016/j.ihj.2025.02.002. Epub 2025 Feb 5.
2
Heparin therapy in sepsis and sepsis-associated disseminated intravascular coagulation: a systematic review and meta-analysis.肝素治疗脓毒症及脓毒症相关弥散性血管内凝血:一项系统评价与荟萃分析。
Thromb J. 2024 Sep 30;22(1):84. doi: 10.1186/s12959-024-00653-0.
3
Unfractionated Heparin Safety in COVID-19: Incidence and Risks of Bleeding Complications in Japan.
肝素钠在 COVID-19 中的安全性:日本出血并发症的发生率和风险。
J Atheroscler Thromb. 2024 Aug 1;31(8):1179-1193. doi: 10.5551/jat.64448. Epub 2024 Feb 14.
4
Thrombosis and Anticoagulation in East Asian Patients With COVID-19: Another Phenotype of "East Asian Paradox".新冠疫情下东亚患者的血栓形成与抗凝治疗:“东亚悖论”的另一种表现形式
JACC Asia. 2022 Dec;2(7):908-911. doi: 10.1016/j.jacasi.2022.10.006. Epub 2022 Dec 15.
5
The technical features of the diagnosis or treatment of coronary artery disease through the distal radial artery approach at the anatomical snuffbox compared with the conventional radial artery approach.经解剖鼻烟窝入路行远端桡动脉途径与传统桡动脉途径诊断或治疗冠状动脉疾病的技术特点比较。
J Cardiothorac Surg. 2022 Sep 7;17(1):231. doi: 10.1186/s13019-022-01979-4.
6
Impact of sheath size and hemostasis time on radial artery patency after transradial coronary angiography and intervention in Japanese and non-Japanese patients: A substudy from RAP and BEAT (Radial Artery Patency and Bleeding, Efficacy, Adverse evenT) randomized multicenter trial.经桡动脉冠状动脉造影和介入治疗后,鞘管大小和止血时间对日本和非日本患者桡动脉通畅率的影响:RAP 和 BEAT(桡动脉通畅率和出血、疗效、不良事件)随机多中心试验的亚研究。
Catheter Cardiovasc Interv. 2018 Nov 1;92(5):844-851. doi: 10.1002/ccd.27526. Epub 2018 Feb 16.
7
Activated clotting time level with weight based heparin dosing during percutaneous coronary intervention and its determinant factors.经皮冠状动脉介入治疗期间基于体重的肝素给药的活化凝血时间水平及其决定因素。
J Cardiovasc Thorac Res. 2014;6(2):97-100. doi: 10.5681/jcvtr.2014.021. Epub 2014 Jun 30.
8
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects.阿哌沙班在健康中国受试者中的单剂量和多剂量药代动力学、药效学及安全性
Clin Pharmacol. 2013 Dec 6;5:177-84. doi: 10.2147/CPAA.S51981. eCollection 2013.
9
Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials.依达肝素或碘达比肝素用于长期静脉血栓栓塞治疗:随机对照试验的系统评价和荟萃分析
PLoS One. 2013 Nov 20;8(11):e78972. doi: 10.1371/journal.pone.0078972. eCollection 2013.
10
Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies.经导管主动脉瓣置换术的当前围手术期抗凝治疗:可否使用比伐卢定?BRAVO 2/3 研究的原理和设计。
J Thromb Thrombolysis. 2013 May;35(4):483-93. doi: 10.1007/s11239-013-0890-3.